Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
Top Cited Papers
Open Access
- 13 October 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 118 (15), 4086-4092
- https://doi.org/10.1182/blood-2011-05-355743
Abstract
Using population-based data from Sweden, we identified all multiple myeloma (MM) patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS) patients diagnosed between 1986 and 2005. We calculated standardized incidence rates (SIRs) for all subsequent hematologic and nonhematologic malignancies for MM patients diagnosed before/after 1995 (introduction of high-dose melphalan/autologous stem cell transplantation [HDM-ASCT]) and 2000 (introduction of immunomodulatory drugs [IMiDs]), respectively. MM patients had an 11.51-fold (95% confidence interval: 8.19-15.74) increased risk of acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS); risk was very similar before/after 1995 and 2000, respectively. MGUS patients had an 8.01-fold (5.40-11.43) increased risk of AML/MDS. Risk was confined to IgG/IgA, while no IgM MGUS patients developed AML/MDS; patients with monoclonal-protein (M-protein) concentrations > 1.5 g/dL (SIR = 11.12; 3.61-25.96) had higher risk than those < 1.5 g/dL (SIR = 4.67; 1.71-10.16). An excess risk of nonmelanoma skin cancer was observed subsequent to both MM (SIR = 2.22; 1.74-2.80) and MGUS (SIR = 3.30; 2.76-3.90). Our novel observations of an excess risk for AML/MDS following IgG/IgA (but not IgM) MGUS, and the highest risk associated with M-protein concentrations > 1.5 g/dL, support a role for nontreatment-related factors in plasma cell dyscrasias. AML/MDS risk following MM was the same before/after the introduction of HDM-ASCT. Longer follow-up is needed to characterize second tumor risks in the IMiD era.This publication has 37 references indexed in Scilit:
- Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based StudyJournal of Clinical Oncology, 2010
- A monoclonal gammopathy precedes multiple myeloma in most patientsBlood, 2009
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009
- Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003Journal of Clinical Oncology, 2007
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceThe New England Journal of Medicine, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999
- Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myelomaEuropean Journal of Cancer and Clinical Oncology, 1983
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaThe New England Journal of Medicine, 1979
- Frequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult PopulationActa Medica Scandinavica, 1966